These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
894 related articles for article (PubMed ID: 33960839)
1. What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery Hadjiargyrou M Nucleic Acid Ther; 2021 Oct; 31(5):321-323. PubMed ID: 33960839 [TBL] [Abstract][Full Text] [Related]
2. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab. Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398 [TBL] [Abstract][Full Text] [Related]
3. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
5. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing. Qiu M; Li Y; Bloomer H; Xu Q Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716 [TBL] [Abstract][Full Text] [Related]
6. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
7. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033 [TBL] [Abstract][Full Text] [Related]
10. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination. Maeda M; Isawa T; Tada N Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122 [No Abstract] [Full Text] [Related]
11. The nano delivery systems and applications of mRNA. Li M; Li Y; Li S; Jia L; Wang H; Li M; Deng J; Zhu A; Ma L; Li W; Yu P; Zhu T Eur J Med Chem; 2022 Jan; 227():113910. PubMed ID: 34689071 [TBL] [Abstract][Full Text] [Related]
12. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
13. Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Baghban R; Ghasemian A; Mahmoodi S Arch Microbiol; 2023 Mar; 205(4):150. PubMed ID: 36995507 [TBL] [Abstract][Full Text] [Related]
14. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328 [TBL] [Abstract][Full Text] [Related]
16. Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies. Li M; Li S; Huang Y; Chen H; Zhang S; Zhang Z; Wu W; Zeng X; Zhou B; Li B Adv Mater; 2021 Aug; 33(34):e2101707. PubMed ID: 34278613 [TBL] [Abstract][Full Text] [Related]
17. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Moghimi SM Mol Ther; 2021 Mar; 29(3):898-900. PubMed ID: 33571463 [No Abstract] [Full Text] [Related]
18. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. Wang Y EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128 [No Abstract] [Full Text] [Related]
19. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. Eliakim-Raz N; Leibovici-Weisman Y; Stemmer A; Ness A; Awwad M; Ghantous N; Stemmer SM JAMA; 2021 Dec; 326(21):2203-2204. PubMed ID: 34739043 [TBL] [Abstract][Full Text] [Related]
20. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]